|4.29||-0.0300||-0.69%||Vol 76.60K||1Y Perf 423.13%|
|Dec 1st, 2023 15:59 DELAYED|
|- -||-0.12 -2.80%|
|Target Price||5.00||Analyst Rating||Strong Buy 1.00|
|Potential %||16.55||Finscreener Ranking||★★+ 47.34|
|Insiders Trans % 3/6/12 mo.||-100/-100/78||Value Ranking||★★ 46.25|
|Insiders Value % 3/6/12 mo.||-100/-100/98||Growth Ranking||★★★ 50.28|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/93||Income Ranking||— -|
|Price Range Ratio 52W %||5.93||Earnings Rating||Strong Buy|
|Market Cap||62.42M||Earnings Date||9th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.94|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||33.95K|
|Avg. Monthly Volume||18.84K|
|Avg. Quarterly Volume||18.64K|
Accelerate Diagnostics Inc. (NASDAQ: AXDX) stock closed at 4.29 per share at the end of the most recent trading day (a -0.69% change compared to the prior day closing price) with a volume of 76.60K shares and market capitalization of 62.42M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 275 people. Accelerate Diagnostics Inc. CEO is John Phillips.
The one-year performance of Accelerate Diagnostics Inc. stock is 423.13%, while year-to-date (YTD) performance is 507.65%. AXDX stock has a five-year performance of -70.95%. Its 52-week range is between 3.81 and 11.9, which gives AXDX stock a 52-week price range ratio of 5.93%
Accelerate Diagnostics Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 89.93, a price-to-sale (PS) ratio of 6.45, a price to cashflow ratio of 213.80, a PEG ratio of -, a ROA of -97.50%, a ROC of -51.28% and a ROE of 324.31%. The company’s profit margin is -%, its EBITDA margin is -474.00%, and its revenue ttm is $9.78 Million , which makes it $0.10 revenue per share.
Of the last four earnings reports from Accelerate Diagnostics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.94 for the next earnings report. Accelerate Diagnostics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Accelerate Diagnostics Inc. is Strong Buy (1), with a target price of $5, which is +16.55% compared to the current price. The earnings rating for Accelerate Diagnostics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Accelerate Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Accelerate Diagnostics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.43, ATR14 : 0.42, CCI20 : -107.21, Chaikin Money Flow : -0.48, MACD : -0.44, Money Flow Index : 9.71, ROC : -18.13, RSI : 28.57, STOCH (14,3) : 20.08, STOCH RSI : 0.51, UO : 35.77, Williams %R : -79.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Accelerate Diagnostics Inc. in the last 12-months were: Brink Frank Jm Ten (Option Excercise at a value of $0), Brown Thomas (Option Excercise at a value of $0), Burris Wayne (Sold 0 shares of value $0 ), David Patience (Sold 0 shares of value $0 ), David Patience (Sold 4 040 shares of value $5 120 ), Francesconi Louise (Option Excercise at a value of $0), Frank J.M. Ten Brink (Option Excercise at a value of $0), Jack Phillips (Option Excercise at a value of $0), Jack Phillips (Sold 367 634 shares of value $180 362 ), Larry Michael Mertz (Option Excercise at a value of $0), Larry Michael Mertz (Sold 33 401 shares of value $16 366 ), Mark C. Miller (Option Excercise at a value of $0), Massarany Hany (Option Excercise at a value of $0), Miller Mark (Option Excercise at a value of $0), Patience David (Option Exercise at a value of $0), Patience David (Sold 92 shares of value $635 ), Phillips Jack (Option Excercise at a value of $0), Phillips Jack (Option Exercise at a value of $0), Phillips Jack (Sold 234 823 shares of value $148 345 ), Schuler Jack (Option Excercise at a value of $0), Steve Reichling (Option Excercise at a value of $0), Steve Reichling (Sold 77 039 shares of value $37 970 ), Steven Reichling (Option Excercise at a value of $0), Steven Reichling (Sold 77 039 shares of value $37 970 ), Watts Charles (Option Excercise at a value of $0)
Mon, 27 Nov 2023 14:16 GMT Accelerate Diagnostics announces collaboration with Bruker- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.